Benitec Biopharma (BNTC) Net Equity Issued and Repurchased (2019 - 2021)

Benitec Biopharma (BNTC) reported Net Equity Issued and Repurchased of $14.3 million for Q2 2021, up 475000.0% sequentially from $3000.0 in Q1 2021.

Benitec Biopharma (BNTC) Net Equity Issued and Repurchased (2019 - 2021) Analysis & Trends

Benitec Biopharma (BNTC) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $14.3 million in Q2 2021.

For the quarter ending Q2 2021, Net Equity Issued and Repurchased changed N/A year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2022 stood at $14.3 million (up 475100.0% YoY), and the FY2023 full-year result was $17.9 million, changed N/A from the prior year.
Net Equity Issued and Repurchased advanced to $14.3 million in Q2 2021, from $3000.0 in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $14.3 million in Q2 2021 to a low of $3000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	141.90 Mn
10	Benitec Biopharma	46.45 Mn	46.45 Mn	-	-

Download Data